Axitinib safety in metastatic renal cell carcinoma: Suggestions for daily clinical practice based on case studies

Sergio Bracarda, Daniel Castellano, Giuseppe Procopio, Juan M. Sepúlveda, Michele Sisani, Elena Verzoni, Manuela Schmidinger

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Axitinib, a highly selective inhibitor of vascular endothelial growth factor receptors taken orally, is approved for second-line treatment of advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. We review data for axitinib and discuss strategies to manage or prevent adverse events (AEs) and maximize clinical benefit. Areas covered: A literature search identified key advanced RCC trials of axitinib and other targeted therapies. Each author also contributed a clinical case study to illustrate management approaches in patients who received axitinib following sunitinib in the AXIS Phase III trial. Axitinib has demonstrated a predictable and manageable AE profile in clinical trials; most commonly reported treatment-related events are diarrhea, hypertension, fatigue, nausea, vomiting and dysphonia. Case studies demonstrate that successful management requires patient awareness of potential AEs, regular monitoring and dose modification for specific AEs. Expert opinion: Improvement in progression-free survival with axitinib versus sorafenib in a Phase III trial supports preferred selection of axitinib in the second-line setting. The safety profile of axitinib versus mammalian target of rapamycin inhibitors and sorafenib also provides the opportunity to personalize treatment in advanced RCC based on the likelihood for specific AEs to occur and on prior toxicities in the first-line setting.

Original languageEnglish
Pages (from-to)497-510
Number of pages14
JournalExpert Opinion on Drug Safety
Volume13
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Renal Cell Carcinoma
Safety
Dysphonia
Vascular Endothelial Growth Factor Receptor
axitinib
Expert Testimony
Sirolimus
Therapeutics
Treatment Failure
Nausea
Disease-Free Survival
Vomiting
Fatigue
Diarrhea
Clinical Trials
Cytokines
Hypertension

Keywords

  • Adverse events
  • AXIS
  • Axitinib
  • Renal cell carcinoma
  • Therapy management

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Axitinib safety in metastatic renal cell carcinoma : Suggestions for daily clinical practice based on case studies. / Bracarda, Sergio; Castellano, Daniel; Procopio, Giuseppe; Sepúlveda, Juan M.; Sisani, Michele; Verzoni, Elena; Schmidinger, Manuela.

In: Expert Opinion on Drug Safety, Vol. 13, No. 4, 2014, p. 497-510.

Research output: Contribution to journalArticle

Bracarda, Sergio ; Castellano, Daniel ; Procopio, Giuseppe ; Sepúlveda, Juan M. ; Sisani, Michele ; Verzoni, Elena ; Schmidinger, Manuela. / Axitinib safety in metastatic renal cell carcinoma : Suggestions for daily clinical practice based on case studies. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. 4. pp. 497-510.
@article{0cc23d45e3e3424f8ba03b5bab52752f,
title = "Axitinib safety in metastatic renal cell carcinoma: Suggestions for daily clinical practice based on case studies",
abstract = "Introduction: Axitinib, a highly selective inhibitor of vascular endothelial growth factor receptors taken orally, is approved for second-line treatment of advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. We review data for axitinib and discuss strategies to manage or prevent adverse events (AEs) and maximize clinical benefit. Areas covered: A literature search identified key advanced RCC trials of axitinib and other targeted therapies. Each author also contributed a clinical case study to illustrate management approaches in patients who received axitinib following sunitinib in the AXIS Phase III trial. Axitinib has demonstrated a predictable and manageable AE profile in clinical trials; most commonly reported treatment-related events are diarrhea, hypertension, fatigue, nausea, vomiting and dysphonia. Case studies demonstrate that successful management requires patient awareness of potential AEs, regular monitoring and dose modification for specific AEs. Expert opinion: Improvement in progression-free survival with axitinib versus sorafenib in a Phase III trial supports preferred selection of axitinib in the second-line setting. The safety profile of axitinib versus mammalian target of rapamycin inhibitors and sorafenib also provides the opportunity to personalize treatment in advanced RCC based on the likelihood for specific AEs to occur and on prior toxicities in the first-line setting.",
keywords = "Adverse events, AXIS, Axitinib, Renal cell carcinoma, Therapy management",
author = "Sergio Bracarda and Daniel Castellano and Giuseppe Procopio and Sep{\'u}lveda, {Juan M.} and Michele Sisani and Elena Verzoni and Manuela Schmidinger",
year = "2014",
doi = "10.1517/14740338.2014.888413",
language = "English",
volume = "13",
pages = "497--510",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Axitinib safety in metastatic renal cell carcinoma

T2 - Suggestions for daily clinical practice based on case studies

AU - Bracarda, Sergio

AU - Castellano, Daniel

AU - Procopio, Giuseppe

AU - Sepúlveda, Juan M.

AU - Sisani, Michele

AU - Verzoni, Elena

AU - Schmidinger, Manuela

PY - 2014

Y1 - 2014

N2 - Introduction: Axitinib, a highly selective inhibitor of vascular endothelial growth factor receptors taken orally, is approved for second-line treatment of advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. We review data for axitinib and discuss strategies to manage or prevent adverse events (AEs) and maximize clinical benefit. Areas covered: A literature search identified key advanced RCC trials of axitinib and other targeted therapies. Each author also contributed a clinical case study to illustrate management approaches in patients who received axitinib following sunitinib in the AXIS Phase III trial. Axitinib has demonstrated a predictable and manageable AE profile in clinical trials; most commonly reported treatment-related events are diarrhea, hypertension, fatigue, nausea, vomiting and dysphonia. Case studies demonstrate that successful management requires patient awareness of potential AEs, regular monitoring and dose modification for specific AEs. Expert opinion: Improvement in progression-free survival with axitinib versus sorafenib in a Phase III trial supports preferred selection of axitinib in the second-line setting. The safety profile of axitinib versus mammalian target of rapamycin inhibitors and sorafenib also provides the opportunity to personalize treatment in advanced RCC based on the likelihood for specific AEs to occur and on prior toxicities in the first-line setting.

AB - Introduction: Axitinib, a highly selective inhibitor of vascular endothelial growth factor receptors taken orally, is approved for second-line treatment of advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. We review data for axitinib and discuss strategies to manage or prevent adverse events (AEs) and maximize clinical benefit. Areas covered: A literature search identified key advanced RCC trials of axitinib and other targeted therapies. Each author also contributed a clinical case study to illustrate management approaches in patients who received axitinib following sunitinib in the AXIS Phase III trial. Axitinib has demonstrated a predictable and manageable AE profile in clinical trials; most commonly reported treatment-related events are diarrhea, hypertension, fatigue, nausea, vomiting and dysphonia. Case studies demonstrate that successful management requires patient awareness of potential AEs, regular monitoring and dose modification for specific AEs. Expert opinion: Improvement in progression-free survival with axitinib versus sorafenib in a Phase III trial supports preferred selection of axitinib in the second-line setting. The safety profile of axitinib versus mammalian target of rapamycin inhibitors and sorafenib also provides the opportunity to personalize treatment in advanced RCC based on the likelihood for specific AEs to occur and on prior toxicities in the first-line setting.

KW - Adverse events

KW - AXIS

KW - Axitinib

KW - Renal cell carcinoma

KW - Therapy management

UR - http://www.scopus.com/inward/record.url?scp=84899105730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899105730&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.888413

DO - 10.1517/14740338.2014.888413

M3 - Article

C2 - 24641566

AN - SCOPUS:84899105730

VL - 13

SP - 497

EP - 510

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -